Skip to main content
. 2022 Apr 17;11(6):766–777. doi: 10.1002/psp4.12789

FIGURE 1.

FIGURE 1

Final log‐linear model for predicting the probability of responding to treatment with isatuximab plus pomalidomide/dexamethasone includes log plasma trough concentration at week 4 (CT4W) and β2‐microglobulin. For a given CT4W value, patients with low β2‐microglobulin values had a higher probability to respond. Solid line represents median. CI, confidence interval; P, percentile; QW, weekly